Brief: Clinuvel Pharmaceuticals Says FDA Relaxes Scenesse Postmarketing Requirement
27/04/2026 02:22
April 27 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX: FDA RELAXES SCENESSE POSTMARKETING REQUIREMENT QT STUDY REMOVED FROM U.S. POST-AUTHORIZATION REQUIREMENTS FOR SCENESSE Further company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist